Company / Total Assets
Amylyx Pharmaceuticals, Inc. Total Assets History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$332.6M
FY2025
5-year range
$105.6M / $517.5M
FY2021-FY2025
Trend
+71.8%
vs FY2024
Sector context
#176 of 214
Health Care
What the data says
Amylyx Pharmaceuticals, Inc.'s total assets of $333M is lower than 82% of companies in the Health Care sector (FY2025). Declined from $517M to $333M over the past 2 years.
Based on SEC 10-K filings.
$333M in FY2025 with a 3-year CAGR of -5.3%.
Declined from $517M to $333M over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- -5.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 18% in Health CareTop 82% of 214This company $332.6M Sector average $7.5B
▼
-95.5% below sector average
Key checks
Key Insights
- 3-year CAGR of -5.3%, indicating a declining trend.
- In FY2025, total assets increased 71.8% year-over-year.
- Ranks #176 out of 214 companies in the Health Care sector.
- Peak total assets was recorded in FY2023.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $332.6M | +71.8% |
| FY2024 | $193.6M | -62.6% |
| FY2023 | $517.5M | +32.2% |
| FY2022 | $391.5M | +270.6% |
| FY2021 | $105.6M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026